HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.

AbstractBACKGROUND:
In many tumors including ovarian cancer, cell proliferation and apoptosis are important in pathogenesis and there are many alterations in most of the genes related to the cell cycle. This study was designed to evaluate immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, and bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in typing of benign, borderline, and malignant serous and mucinous ovarian tumors.
METHODS:
Total of 68 ovarian tumors, 25 benign [13 (19.1%) serous and 12 (17.6%) mucinous], 16 borderline [9 (13.2%) serous and 7(10.3%) mucinous], and 27 malignant ovarian tumors [24 (35.3%) serous and 3 (4.4%) mucinous tumors] were included in the study. Immunohistochemical expression of p53, p21, bax, bcl-2, telomerase, c-kit, and metallothionein were evaluated.
RESULTS:
When all 68 cases were evaluated as benign, borderline, and malignant ovarian tumors without considering histopathological subtypes, the p53, p21, bax and metallothionein showed significantly higher staining scores in the borderline and malignant ones (p < 0.05). After evaluation of all 68 cases, the serous tumors showed significantly higher staining scores of p53, p21, c-kit, and metallothionein compared to the mucinous ones (p < 0.05). For differentiation of benign and borderline and malignant tumors combined, p53 was not used because all benign tumors has no staining, and p21, bax, and metallothionein was determined the significant predictors for borderline and malignant tumors combined (p < 0.05). For differentiation of borderline and malignant tumors, only p53 was determined the significant predictor for malignant tumors (p < 0.05).
CONCLUSIONS:
In conclusion, p53, p21, bax, c-kit, and metallothionein may be helpful for the typing of ovarian tumors as benign, borderline and malignant or serous and mucinous. p53, p21, bax, c-kit, and metallothionein may have different roles in the pathogenesis of ovarian tumor types. p53 and metallothionein may be helpful in the typing of borderline and malignant ovarian tumors. The immunohistochemical staining with bcl-2 and telomerase may not provide meaningful contribution for the typing of ovarian tumors.
VIRTUAL SLIDE:
The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2013030833768498.
AuthorsHatice Ozer, Goncaimir Yenicesu, Sema Arici, Meral Cetin, Ersin Tuncer, Ali Cetin
JournalDiagnostic pathology (Diagn Pathol) Vol. 7 Pg. 124 (Sep 20 2012) ISSN: 1746-1596 [Electronic] England
PMID22995373 (Publication Type: Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • BAX protein, human
  • Biomarkers, Tumor
  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Proto-Oncogene Proteins c-bcl-2
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • bcl-2-Associated X Protein
  • Metallothionein
  • Proto-Oncogene Proteins c-kit
  • Telomerase
Topics
  • Adult
  • Aged
  • Analysis of Variance
  • Apoptosis
  • Biomarkers, Tumor (analysis)
  • Cyclin-Dependent Kinase Inhibitor p21 (analysis)
  • Female
  • Humans
  • Immunohistochemistry
  • Logistic Models
  • Metallothionein (analysis)
  • Middle Aged
  • Neoplasms, Cystic, Mucinous, and Serous (chemistry, classification, diagnosis, pathology)
  • Ovarian Neoplasms (chemistry, classification, diagnosis, pathology)
  • Predictive Value of Tests
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 (analysis)
  • Proto-Oncogene Proteins c-kit (analysis)
  • Telomerase (analysis)
  • Tumor Suppressor Protein p53 (analysis)
  • bcl-2-Associated X Protein (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: